Rapid eGFR Decline and Cost Barriers in Type 2 Diabetes
R.M., 68, is seen in your ambulatory clinic for a 6-month diabetes visit. A1c 8.9% (prior 8.4%), BP 142/82, weight 96 kg, eGFR 32 mL/min/1.73 m² (41 one year ago), urine albumin-to-creatinine ratio 350 mg/g, potassium 5.1 mmol/L (4.6 six months ago), hemoglobin 10.8 g/dL. Medications: metformin 1000 mg twice daily, glipizide 10 mg daily, lisinopril 40 mg daily, atorvastatin 40 mg daily, furosemide 20 mg as needed. He reports two episodes of shakiness before lunch last week, skips lunch often because he works nights, and has no glucose meter. Metformin and sulfonylureas cost him $5/month; SGLT2 inhibitors require prior authorization and cost $75/month, and he says flatly, "I can't do that."
1. Which of his current medications require action today, and in what order of priority?
Read the worked answer
1. Metformin - reduce, do not stop. eGFR fell 41 → 32 in 12 months. At eGFR 30–44, metformin may be continued but should not be initiated, and many guidance sources cap the dose near 1000 mg/day. Drop to 500 mg twice daily, recheck eGFR in 3 months, and stop if eGFR falls below 30.
2. Glipizide - reduce or stop. Two pre-lunch hypoglycemia episodes plus habitual meal skipping plus progressive CKD (reduced insulin clearance) is a stacked risk. Cut to 5 mg or discontinue before adding anything new; sulfonylureas carry the highest hypoglycemia burden of his regimen.
3. The A1c itself is suspect. Hemoglobin 10.8 g/dL with CKD raises the odds of iron/B12 deficiency and shortened red-cell survival, both of which falsely lower A1c. Treating to 8.9% when true glycemia may be higher risks overtreatment elsewhere. Order iron studies, B12, and consider CGM (Medicare covers CGM with problematic hypoglycemia) or fructosamine.
4. Kidney protection is the highest long-term-yield change but is currently blocked by cost - address it in parallel, not instead of the safety fixes.
2. How do you handle the SGLT2 inhibitor conversation given his eGFR and his stated cost refusal?
Read the worked answer
This is an albuminuric CKD patient (UACR 350, eGFR 32) with diabetes - SGLT2 inhibitor therapy has kidney and cardiovascular benefit down to eGFR 20–25 depending on agent, so it is not optional nicety. But respecting the stated barrier is part of the clinical decision.
- Do not simply accept "no." Confirm what $75 actually means against his budget; sometimes it is refill friction or prior-authorization paperwork, not the dollar figure.
- Work the access channels in order: prior authorization with documentation of CKD indication; manufacturer patient assistance or copay support (note Medicare Part D rules limit copay cards - patient assistance programs may still apply); 340B pricing if the site is eligible; check the formulary for a lower-tier agent in the class.
- Sequence it: fix metformin and glipizide first, then start the SGLT2 inhibitor when coverage is confirmed. Set a concrete follow-up (2–4 weeks) so this does not evaporate.
- Explain the offer in his terms: fewer kidney-function drops and fewer heart-failure admissions, not "guideline says."
- If access truly fails, document the attempt, maximize lisinopril tolerability, and revisit at every visit; a GLP-1 receptor agonist with kidney benefit is an alternative only if coverage is better, which is unlikely at this copay level.
3. Potassium is 5.1 mmol/L. What is your assessment and next step?
Read the worked answer
K 5.1 with eGFR 32 is mild hyperkalemia and a predictable consequence of ACE inhibitor plus CKD - but it is not a reason to stop lisinopril. With UACR 350 mg/g, the ACE inhibitor is doing the most renoprotective work in his regimen.
Rule out artifact and contributors first:
- Hemolysis or prolonged tourniquet time on the draw; repeat a non-hemolyzed sample.
- Dietary potassium, salt substitutes (potassium chloride), supplements, NSAIDs, trimethoprim.
- Metabolic acidosis - check a bicarbonate; CKD-related acidosis both raises potassium and responds to alkali.
- Furosemide adherence and volume status; a low effective diuretic dose contributes.
Action plan: repeat BMP in 1–2 weeks with dietary review (no salt substitutes), counsel on high-potassium foods, and set an explicit threshold: if K ≥5.5 or rises further, reduce lisinopril rather than stop, and address acidosis. Starting an SGLT2 inhibitor would actually lower his potassium and would help here - another reason to keep pushing on access.
Document that the hyperkalemia is being managed, not ignored, so the next clinician does not reflexively discontinue the ACE inhibitor.